Shares in American biotech company Gilead Sciences Inc. climbed to a more than six-month high this week on news that it had been given the green light to start human trials of an experimental antiviral drug on coronavirus patients in China.
Shares in American biotech company Gilead Sciences Inc. climbed to a more than six-month high this week on news that it had been given the green light to start human trials of an experimental antiviral drug on coronavirus patients in China.
365体育 |
宝发彩票-首页 |
090彩票平台 |
www..88必发.com |
幸福彩票官方 |
网投平台pk10 |
广东体彩手机 |
一品彩票平台 |
皇冠现金足球投注网 |